Stay updated with breaking news from Johnson Edurant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Just over a year after approving GlaxoSmithKline and ViiV Healthcare's Cabenuva as a long-acting alternative to daily pills for HIV patients, the FDA has made the treatment more convenient, expanding its dosage option from monthly to once every two months.
Dive Brief: GlaxoSmithKline, through its majority-owned subsidiary, ViiV Healthcare, is now cleared to sell a long-acting, injectable HIV medicine, providing the U.K. company with a potentially valuable tool as its competes against market-leading drugs from Gilead. On Thursday, the Food and Drug Administration approved the medicine, which now has the brand name Cabenuva, as a replacement treatment for certain adults whose HIV infections are in check from other therapies. Cabenuva is given once a month, and is a combination of a GSK drug called cabotegravir and the active ingredient in Johnson...